The U.S. section of Abbottep.com is a product-specific website that is NOT intended for non U.S. residents. This web content is exclusively reserved for health care professionals in the United States.

Do you wish to continue to visit the Abbottep.com U.S. section?

Get your rhythm back.

Serious heart rhythm disorders called arrhythmias, affect the lives of millions of people daily. Unfortunately, most treatments for these conditions are generic and one-size-fits-all, with mixed results.

But there’s hope.

We believe there is a better way to address serious heart rhythm disorders such as atrial fibrillation and ventricular tachycardia. Using Abbott Electrophysiology’s technology, doctors can identify the sources of arrhythmias that are unique to each person. Now treatment can be tailored to your individual needs.

Find Your Source.
Get Tailored Therapy.
Get Your Rhythm Back.

Find a doctor near you who is using the Topera Rotor Mapping System

The most common heart rhythm disorder, atrial fibrillation (AF, or afib) is a serious global public health problem which affects millions of people around the world. If left untreated, AF doubles the risk of heart-related deaths and also increases stroke risk by up to 500%. Unfortunately, although it is such a serious health problem, AF has historically been difficult to treat with an acceptable degree of success.

In response to this unaddressed need, Abbott, Inc. has developed a unique 3D analysis and mapping solutions (the Abbott 3D Mapping System), which consists of the RhythmView Workstation and FIRMap diagnostic catheter. The Abbott 3D Mapping System has been designed to enable physicians to view the electrical activity of the heart, thereby supporting the diagnosis and patient-specific treatment planning for a variety of heart arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia and ventricular tachycardia.

The Abbott 3D Mapping System received FDA Clearance in 2013 band is now in routine use at several leading medical centers throughout the United States.

High-Risk Patients

Success in High-Risk Patients1


Cardiac ablation is one of many Afib treatment options. The authors hypothesized that comorbid conditions such as obesity, heart failure, obstructive sleep apnea (OSA), and enlarged left atria (LA) may cause higher numbers or non-PV (pulmonary vein) locations of atrial fibrillation (AF or Afib) sources, where targeted source ablation (focal impulse and rotor modulation or FIRM) could improve the single procedure success of ablation.


To determine if FIRM-guided rotor elimination improves single-procedure success in high-risk AF patients by reviewing a subset of patients from the Conventional Ablation of AF With or Without Focal Impulse and Rotor Modulation (CONFIRM)2 trial.


The CONFIRM trial prospectively enrolled 92 patients at 107 AF ablation heart procedures, in whom computational mapping identified AF rotors or focal sources. Patients underwent FIRM plus conventional ablation (FIRM-guided), or conventional ablation only, and were evaluated for recurrent AF quarterly with rigorous, often implanted monitoring. The authors reported the n = 73 patients undergoing first ablation in whom demographic information was available (n = 52 conventional, n = 21 FIRM-guided). The only exclusion was inability or refusal to provide written consent.

Key Findings

  • Stable sources for AF were found in 97.1% of patients.
  • The distribution of rotor locations was more widespread in high-risk patients (obese, OSA, persistent AF, heart failure).

  1. Baykaner T, Clopton P, Lalani GG, AA Schricker, Krummen DE, and Narayan SM. Targeted Ablation at Stable Atrial Fibrillation Sources Improves Success Over Conventional Ablation in High-Risk Patients: A Substudy of the CONFIRM Trial. Canadian J Cardiol. 2013; 29:1218-1226.
  2. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel W-J, and Miller JM. Treatment of Atrial Fibrillation by the Ablation of Localized Sources-CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) Trial. J Am Coll Cardiol 2012; 60(7):628-3


These trials were supported by grants to the lead author from the National Institutes of Health and the Doris Duke Charitable Foundation. Please refer to the study citations to review all reported author conflicts of interest.